Your browser doesn't support javascript.
loading
An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patient.
Quancard, Jean; Klein, Theo; Fung, Shan-Yu; Renatus, Martin; Hughes, Nicola; Israël, Laura; Priatel, John J; Kang, Sohyeong; Blank, Michael A; Viner, Rosa I; Blank, Jutta; Schlapbach, Achim; Erbel, Paul; Kizhakkedathu, Jayachandran; Villard, Frédéric; Hersperger, René; Turvey, Stuart E; Eder, Joerg; Bornancin, Frédéric; Overall, Christopher M.
Affiliation
  • Quancard J; Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland. jean.quancard@novartis.com.
  • Klein T; Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada.
  • Fung SY; Department of Oral Biological and Medical Science, Faculty of Dentistry, University of British Columbia, Vancouver, British Columbia, Canada.
  • Renatus M; Center for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.
  • Hughes N; Department of Clinical Chemistry, Erasmus MC University Medical Center, Rotterdam, Netherlands.
  • Israël L; Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
  • Priatel JJ; BC Children's Hospital, Vancouver, British Columbia, Canada.
  • Kang S; Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland.
  • Blank MA; Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland.
  • Viner RI; Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland.
  • Blank J; Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
  • Schlapbach A; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Erbel P; Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
  • Kizhakkedathu J; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Villard F; Thermo Fisher Scientific, San Jose, CA, USA.
  • Hersperger R; AbbVie Biotherapeutics, Inc., Redwood City, CA, USA.
  • Turvey SE; Thermo Fisher Scientific, San Jose, CA, USA.
  • Eder J; Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland.
  • Bornancin F; Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland.
  • Overall CM; Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland.
Nat Chem Biol ; 15(3): 304-313, 2019 03.
Article in En | MEDLINE | ID: mdl-30692685
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein Type of study: Prognostic_studies Limits: Humans / Male Language: En Journal: Nat Chem Biol Journal subject: BIOLOGIA / QUIMICA Year: 2019 Document type: Article Affiliation country: Switzerland Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein Type of study: Prognostic_studies Limits: Humans / Male Language: En Journal: Nat Chem Biol Journal subject: BIOLOGIA / QUIMICA Year: 2019 Document type: Article Affiliation country: Switzerland Country of publication: United States